Cytomegalovirus (CMV) is a common virus that infects many people. It can cause serious illness in people with weak immune systems especially in those undergoing transplants. Maribavir is a medicine approved for treating CMV infection in adults after transplant. The main aim of this study is to check the use of maribavir and learn how safe and effective in treating adults with CMV infection after transplant in Belgium in line with the Belgian reimbursement criteria. During the study, a participant's data will be collected for 2 years. The study does not have fixed visits to the hospital, but it is recommended collect data from routine visits and contacts.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of Participants With Effectiveness of Maribavir on CMV Viremia Clearance
Timeframe: Up to 16 weeks
Duration of Treatment
Timeframe: From treatment start to discontinuation of maribavir (up to 16 weeks)
Time to Viral Clearance
Timeframe: From treatment start to achievement of viral clearance (up to 2 years)
Percentage of Participants With Drug Resistance
Timeframe: Up to 2 years
Number of Participants With Use of Maribavir in Daily Clinical Practice
Timeframe: Up to 16 weeks
Number of Participants Who Have Refractory CMV Infection With/Without Resistance, or Intolerance to a Previous CMV Treatment
Timeframe: Up to 16 weeks
Percentage of Participants With Recurrence After Maribavir Treatment
Timeframe: Up to 2 years
Number of Participants With Treatment Related Adverse Events (AEs)
Timeframe: Up to 2 years